← Back to Search

Monoclonal Antibodies

SGN-CD228A for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Seagen Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 3.5 years

Awards & highlights

Study Summary

This trial will study whether SGN-CD228A is an effective treatment for different kinds of cancer, and what side effects may occur.

Eligible Conditions

Non-Small Cell Lung Cancer
Colorectal Cancer
Breast Cancer
Mesothelioma
Skin Cancer
Pancreatic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 3.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 3.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with adverse events

Number of participants with dose limiting toxicities

Number of participants with laboratory abnormalities

Secondary outcome measures

AUC(0-last) of free MMAE

AUC(0-last) of total antibody

Area under the plasma concentration-time curve from time 0 to the last available [AUC (0-last)] of acMMAE

+17 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: SGN-CD228AExperimental Treatment1 Intervention

SGN-CD228A monotherapy

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor

207 Previous Clinical Trials

69,069 Total Patients Enrolled

Phillip Garfin, MD, PhDStudy DirectorSeagen Inc.

3 Previous Clinical Trials

175 Total Patients Enrolled

Anu Gupta, MDStudy DirectorSeagen Inc.

1 Previous Clinical Trials

58 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently an opportunity to join this clinical experiment?

"Affirmative, according to clinicaltrials.gov this study is actively seeking participants. First posted on September 3rd 2019 and last revised October 28th 2022, it's currently recruiting 210 individuals from 11 different medical locations."

Answered by AI

Has the FDA sanctioned SGN-CD228A for public use?

"This medication's safety was appraised as a 1 due to the limited amount of research backing its efficacy and security. This is because it is currently in Phase 1 clinical trials."

Answered by AI

How widely has this investigation been disseminated in the US?

"11 clinical trial sites are taking on patients, with notable examples such as The Angeles Clinic and Research Institute in Los Angeles, MD Anderson Cancer Center / University of Texas in Houston, and Oregon Health and Science University in Portland."

Answered by AI

How many participants are included in the current investigation?

"Seagen Inc. has set a target of 210 eligible participants for this trial, and will recruit them from The Angeles Clinic and Research Institute in Los Angeles as well as MD Anderson Cancer Center / University of Texas in Houston."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of SGN-CD228A in Advanced Solid Tumors

2019. "A Study of SGN-CD228A in Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04042480.